All In Biotech

NDA 207953 · Janssen Prods

Yondelis

Trabectedin · Intravenous · Alkylating Drug

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 23, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

89

18 Phase 3, 12 recruiting

FAERS reports

2,350

2,142 serious, 464 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 6, 2026.

YONDELIS ® is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] . YONDELIS is an alkylating drug indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1 )

Mechanism: Trabectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • YONDELIS · TRABECTEDIN 1MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trabectedin" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neutropenia251
  • anaemia214
  • nausea206
  • thrombocytopenia202
  • febrile neutropenia163
  • pancytopenia161
  • off label use154
  • vomiting151
  • disease progression139
  • rhabdomyolysis132
  • alanine aminotransferase increased125
  • asthenia107

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
20077
20086
20094
201012
201144
201227
201328
201435
201582
2016344
2017254
2018266
2019213
2020151
2021132
2022157
2023153
2024173
2025127
2026133

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Yondelis (Trabectedin)

2024 spending

$355K

Beneficiaries

n/a

42 claims

Per beneficiary

n/a

$3,352.03 per unit

View as table
YearSpending
2020$258,465
2021$371,519
2022$109,538
2023$577,821
2024$355,315

Part B: Yondelis (Trabectedin) · HCPCS J9352

2024 spending

$16.1M

Beneficiaries

426

1,765 claims

Per beneficiary

$37,759

2024 ASP limit $348.74 per unit

View as table
YearSpending
2020$9,458,687
2021$9,056,753
2022$11,938,777
2023$12,203,518
2024$16,085,534

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 125 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.